Tradestie Institutional Equity Comparison Engine

RENX vs CDIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CDIO Overall Edge

CDIO Captures Institutional Edge (1โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cardio Diagnostics Holdings Inc. Common stock (CDIO) driven by superior Growth & Margin while RENX counters with relative strength in Momentum & Technical. Fundamentally, RENX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CDIO at N/M Forward P/E and -42649.8% operating margin (+25.7% YoY). In options structure, RENX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CDIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RENX N/M vs CDIO N/M Fwd P/E
Growth & Margin Winner CDIO
Op Margin N/A vs -42649.8% ยท YoY N/A vs +25.7%
Momentum & Technical Winner RENX
1Y +163.6% vs -37.5% ยท 52W Pos 19% vs 9%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RENX US Equity
RENX
Institutional Equity
$0.74
-23.09% 1D
Market Cap N/A
1M Return -48.21%
1Y Return +163.59%
Forward P/E N/M
Unified AI Score
44.0 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 64.0
CDIO NASDAQ
Cardio Diagnostics Holdings Inc. Common stock
In Vitro & In Vivo Diagnostic Substances
$1.60
-3.03% 1D
Market Cap $4.9M
1M Return -6.16%
1Y Return -37.5%
Forward P/E N/M
Unified AI Score
47.2 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RENX +163.59% CDIO -37.5% Spread: +212.13 pp (RENX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RENX TTM Op. Margin: N/A CDIO TTM Op. Margin: -42649.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RENX vs CDIO. Trailing 12-month operating profitability (RENX N/A vs CDIO -42649.8%) and valuation multiples (RENX N/M vs CDIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RENX (1) vs CDIO (7)
Institutional Metric RENX CDIO Criterion Row Winner
Market Capitalization Scale N/A $4.9M Larger Scale CDIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +25.7% Higher Growth CDIO
Operating Margin (TTM) Profitability N/A -42649.8% Higher Margin CDIO
Net Profit Margin Profitability N/A 0.0% Higher Margin CDIO
Return on Equity (ROE) Capital Efficiency N/A -93.5% Higher ROE CDIO
52-Week Range Position Momentum 19% ($0โ€“$3) 9% ($1โ€“$8) Stronger Trend RENX
Beta / 30D Volatility Risk Regime -17.85ฮฒ ยท 161% Vol 1.36ฮฒ ยท 56% Vol Lower Realized Risk CDIO
Unified Institutional Score Composite Signal 44.0 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite CDIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RENX vs CDIO Buy Guide
RENX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RENX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CDIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CDIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RENX nor CDIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.